Aachen, Germany and Gothenburg, Sweden, 14 December 2018 – Grünenthal and OnDosis announced today that they have entered into an exclusive collaboration to develop the OnDosis’ technology for prescription medicines in all pain related indications. The agreement also entails an option for Grünenthal to an exclusive worldwide license to the technology in these indications. The handheld device enables individualised dosing of oral medicines in micro units, provides support for patient compliance, can be combined with digital solutions and thus significantly improves patients’ safety. The agreement with Grünenthal, a leading pain specialist, is the first partnering deal for life science startup OnDosis on their innovative technology. While this agreement covers the indication area pain; other focus areas of OnDosis, like ADHD and immunosuppression, remain available for further cooperation with third parties.